Washington, D.C. – Foley & Lardner LLP announced today that David L. Rosen and Steven A. Maddox have joined the firm, bringing their extensive pharmaceutical experience to the firm’s Life Sciences Industry Team. Both Maddox, an experienced pharmaceutical patent litigator, and Rosen, a 14-year veteran of the Food and Drug Administration with special emphasis in pharmaceutical issues, joined from DLA Piper Rudnick Gray Cary. This announcement marks the latest step in Foley & Lardner’s national nicheing strategy to add breadth and depth in key practice areas to complement the firm’s strengths.
“The addition of these two attorneys is of strategic importance because their strong pharmaceutical industry experience further enhances our service offerings to clients,” said Stephen Bent, co-chair of Foley & Lardner’s Life Sciences Industry Team.
“While David brings his perspective of dealing with pharmaceutical industry issues at the FDA and serving these clients in private practice, Steven has a long career litigating pharmaceutical patent infringement cases,” Bent said.
The addition of Maddox and Rosen follows on the heels of Foley & Lardner’s acquisition in January of the Boston office of Epstein, Becker & Green, which enhanced the firm’s Life Sciences practice. In 2004 the firm also opened New York and Silicon Valley offices as part of its strategic plan to increase its presence in key life sciences markets.
Steven Maddox, who will be a partner in the firm’s IP Department, IP Litigation Practice Group and Life Sciences Industry Team, has extensive experience litigating a variety of patent cases, with special expertise in Hatch-Waxman Act pharmaceutical cases. He assists clients in the fields of pharmaceuticals, medical devices, semiconductor manufacturers, hardware and software. His clients have included Andrx Pharmaceuticals, Three Rivers Pharmaceuticals and Cobalt Pharmaceuticals.
David Rosen joins Foley & Lardner as a partner in the Regulatory Department and the Life Sciences Industry Team. A pharmacist with a distinguished 14-year career at the U.S. Food and Drug Administration and 13 years in private practice, he has been involved in all aspects of the drug review and approval process, advertising and promotion and related compliance and enforcement activities. Rosen has a broad-based FDA regulatory practice and handles issues affecting prescription and over-the-counter pharmaceuticals, medical devices, biologics, dietary supplements, foods and pharmacy-related matters.
Foley & Lardner LLP has nearly 1,000 attorneys in 20 offices. Its practice includes corporate governance, securities enforcement, litigation, merger and acquisitions, intellectual property and IP litigation, labor and employment, and tax with particular emphasis in the automotive, e-business and information technology, energy, financial services, food, golf and resort services, insurance, health care, life sciences, nanotechnology, and sports industries. The firm’s Web site can be found at www.foley.com.
